In summary, this study highlights the favorable clinical diagnostic value of IL-2 in patients with PDAC for the first time and confirms that IL-2 can enhance the efficacy of DC-based tumor vaccines both in vitro and in vivo, providing a promising new approach for PDAC immunotherapy. The gene discussed is IL2; the disease is neoplasm.